clinical trial · NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 590
Bladder CancerSacituzumab tirumotecanVinflunineDocetaxelPaclitaxelRescue medications for sacituzumab tirumotecanRescue medications for chemotherapy
brief summary
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
started
Apr 30, 2026
primary completion
Jul 27, 2029
completion
Apr 23, 2030
last updated
Apr 24, 2026
official title
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol